title: Improvement of an experimental colitis in rats by lactic acid bacteria producing superoxide dismutase.
abstract: The use of superoxide dismutases (SODs) in inflammatory diseases is hampered by their short circulatory half-life. To determine whether a bacterial supply of SOD into the colon might improve an experimental colitis, the effects of oral treatment with live recombinant lactic acid bacteria producing different amounts of SOD and those of colonic infusion of SOD were compared. Wistar rats were fitted with a catheter in the proximal colon through which TNBS was administered to induce colitis. Animals received a continuous intracolonic infusion of bovine SOD (40 U per rat per day) for 4 days after TNBS or were treated orally with live recombinant Lactococcus lactis or Lactobacillus plantarum strains (10 colony-forming units (CFU)/d), producing or not producing SOD, for 4 days before and after TNBS. SOD activity of bacterial extracts was 0, 26, 74, and 624 units/10 CFU for L. plantarum, L. lactis, L. lactis SOD, and L. plantarum SOD, respectively. Four days after TNBS, macroscopic and microscopic damage, myeloperoxidase (MPO) activity, and nitrotyrosine immunostaining were evaluated. TNBS induced macroscopic and microscopic damages, an increase in MPO activity, and intense immunostaining for nitrotyrosine. Macroscopic damage and MPO activity were reduced by bovine SOD. These parameters and microscopic damages also were reduced by L. lactis, L. lactis SOD, and L. plantarum SOD, but not by L. plantarum. Nitrotyrosine immunostaining was attenuated after treatment with the 4 bacterial strains. Although not all of the anti-inflammatory effects could be attributed directly to SOD, our results suggest that SOD-producing lactic acid bacteria open a novel approach in inflammatory bowel disease treatment.
authors.affiliation: Neurogastroenterology and Nutrition Unit, Institut National de la Recherche Agronomique, Toulouse, France.
authors.forename: Wei
authors.initials: W
authors.lastname: Han
authors.forename: Annick
authors.initials: A
authors.lastname: Mercenier
authors.forename: Afifa
authors.initials: A
authors.lastname: Ait-Belgnaoui
authors.forename: Sonia
authors.initials: S
authors.lastname: Pavan
authors.forename: Florence
authors.initials: F
authors.lastname: Lamine
authors.forename: Iris I
authors.initials: II
authors.lastname: van Swam
authors.forename: Michiel
authors.initials: M
authors.lastname: Kleerebezem
authors.forename: Christel
authors.initials: C
authors.lastname: Salvador-Cartier
authors.forename: Michael
authors.initials: M
authors.lastname: Hisbergues
authors.forename: Lionel
authors.initials: L
authors.lastname: Bueno
authors.forename: Vassilia
authors.initials: V
authors.lastname: Theodorou
authors.forename: Jean
authors.initials: J
authors.lastname: Fioramonti
mesh_terms: D000284:Administration, Oral; D000818:Animals; D002417:Cattle; D003092:Colitis / Q000201:enzymology / Q000382:microbiology / Q000473:pathology / Q000628:therapy*; D007150:Immunohistochemistry; D007778:Lactobacillus / Q000201:enzymology* / Q000378:metabolism; D008297:Male; D009195:Peroxidase / Q000378:metabolism; D019936:Probiotics / Q000627:therapeutic use; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D013482:Superoxide Dismutase / Q000008:administration & dosage / Q000096:biosynthesis*; D014302:Trinitrobenzenesulfonic Acid
chemical_list: D014302:Trinitrobenzenesulfonic Acid; D009195:Peroxidase; D013482:Superoxide Dismutase